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Parenteral drug errors
Reported error rates are likely 
to be underestimation
The reported error rates in Valentin and 
colleagues’ study on errors in administration of 
parenteral drugs in intensive care units are likely 
to underestimate the true incidence of errors.1
Firstly, errors were identified using self 
reporting by hospital staff. Only about 1 in 100 
prescribing errors and 1 in 1000 administration 
errors are reported using established incident 
reporting systems.2 3 The error rate was 7% of all 
doses given, which is substantially lower than 
the error rates of 18-173% found in other studies 
in intensive care and other wards using the “gold 
standard” of independent observers.4 5
Secondly, the authors assessed only five 
specific types of error. Other potentially common 
administration errors associated with parenteral 
treatment, including use of the wrong diluent, 
incompatibility errors, and wrong administration 
rates, seem to have been excluded. Conducting 
regression analyses on the basis of a potentially 
small subset of reported errors is therefore likely 
to be flawed.
Valentin and colleagues gave no information 
on the role of pharmacists, although pharmacists 
are routinely part of the critical care team in 
many of the countries included. Pharmacists 
reduce adverse events due to prescribing 
errors in critical care, and having a pharmacist 
in a multidisciplinary team is likely also to be 
associated with reduced administration errors.
We advocate the use of independent 
observers collecting data on actual practice to 
understand the true incidence and causes of 
administration errors in intensive care,5 as well 
as controlled studies to identify the true impact 
of interventions.
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HyPertension in young PeoPle
Who to investigate?
Hammer and Stewart suggest that ambulatory 
blood pressure measurement in young people 
with hypertension is warranted “if white coat 
hypertension is suspected” without giving any 
guidance about how it might be suspected.1 It is 
a popular misconception that such individuals 
can be identified by any clinical characteristic, 
so you either perform ambulatory monitoring on 
every young person with high blood pressure 
(shown to be cost effective) or check self 
monitored blood pressure first (as promoted 
by the American Society of Hypertension). UK 
guidelines do not help us. The authors suggest 
investigation for a secondary cause in people 
under 40. British guidelines say under 30, but 
any figure will be a little arbitrary. To perform a full 
screen for a secondary cause in anyone under 40 
(this being the only criterion) would be expensive 
and without an evidence base.
To say that primary hyperaldosteronism 
accounts for 5-10% of all hypertension is 
misleading. The authors define it as starting with 
a screening test with a high plasma aldosterone 
concentration and suppressed plasma renin 
activity. If so, then the prevalence will be much 
lower than 10%, or even 5%. When the definition 
shifts (as it does in the learning points box) to 
describe the ratio of aldosterone to renin, the 
prevalence seems to increase.
As the ratio of aldosterone to renin is largely 
driven by plasma renin activity, the concomitant 
use of β blockers, which suppress renin, should 
not be allowed at the time of testing.
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transient iscHaemic attack
Giant cell arteritis and transient 
visual loss
Monocular transient visual loss due to emboli 
or ocular hypoperfusion usually occurs in 
isolation rather than accompanying a transient 
neurological deficit.1 Adhiyaman and Adhiyaman 
did not mention that giant cell arteritis is an 
important cause of transient visual loss in their 
10 minute consultation on transient ischaemic 
attack.2 Transient visual loss occurred in over 
30% of patients with giant cell arteritis and 
ophthalmic involvement in one series and is 
a strong predictor of permanent visual loss.3 4 
Delayed diagnosis and treatment of giant cell 
arteritis is associated with bilateral blindness in 
patients with visual symptoms.4
The authors also do not mention measuring 
inflammatory markers in the recommended 
investigation of transient ischaemic attack,2 
but we would advise checking erythrocyte 
sedimentation rate, C reactive protein, and 
platelet count in older patients with transient 
monocular visual loss. High dose glucocorticoid 
treatment (prednisolone 1 mg/kg, maximum 60 
mg, or pulsed methylprednisolone) should be 
started before temporal artery biopsy in patients 
with suspected giant cell arteritis.5
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Quality in Primary HealtH care
a simple approach to quality 
“When I use a word, it means just what I choose 
it to mean—neither more nor less,” said Humpty 
Dumpty. Today’s word is “quality,” and Heath 
and colleagues’ specific vagueness of the “way 
forward” to measure quality in primary care 
suggests we won’t be able 
agree what we mean for  
many years.1
“If you don’t know where you 
are going, any road will get you 
there,” said the Cheshire Cat. 
Quality is not a destination: 
it’s a journey of aspiration 
and achievement rather than 
completion. It will always mean different things to 
different people at different times.
The problem with the quality journey is that, 
although we may know what route we think we 
need to take, we don’t know where we are going, 
or when we are going to get there. Guides like the 
quality and outcome framework (QOF) are like 
satellite navigation: authoritative and useful but 
sometimes prone to error at critical junctions.
We are not there yet, but over the past 20 years 
our journey has advanced considerably with more 
aspirations for outcomes and real achievements 
in the structure and processes for quality in 
primary care. Imperfect as QOF is, it is an example 
of the vertical advance. Examples of other more 
horizontal advances include the quality practice 
award, appraisals, and the core curriculum. QOF 
confirms that rapid advance in any direction is 
fuelled by financial incentives.
A simple approach to quality as we continue on 
our journey is to run through an A to F checklist on 
our dashboard to make sure we are still headed in 
the right direction.2 Always check: A, we provide 
good access to our service, B, the best treatments 
are available, C, the customers are satisfied with 
the service, D, we provide a depth of care, E, the 
service is efficient and effective, and F, we treat 
everyone fairly.
Lewis Carroll’s advice: “Begin at the beginning 
and go on till you come to the end; then stop.”
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The shaman and QoF
Heath and colleagues use a case study of a 
person who has hypertension and a complex 
tale which includes oesophageal cancer, 
bronchiectasis, and a sorry family history to 
question whether the achievement of a blood 
pressure of 150/90 mm Hg in any way assesses 
quality of care.1 We don’t know what the patient’s 
blood pressure is, and, more crucially, what the 
patient wants to do about it.
The quality and outcomes framework (QOF) 
is explicit about exemption reporting: if the 
patient does not wish to have treatment she 
can be exempted at no 
loss to practice income. It 
is then up to the doctor to 
discuss with the patient what 
she wants to do about her 
blood pressure, not decide 
for her. QOF is then about 
empowering patients rather 
than invoking professionalism 
and complexity, which can encourage doctors to 
continue in their paternalistic ways. Appealing 
to complexity, and therefore almost invoking 
the shaman in general practice, can lead to 
disempowerment of patients. Such an approach 
needs to be handled with as much care as the 
overenthusiastic application of guidelines.
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euroPean Working time directive
Running out of time? 
Richards sums up the conflicting views on the 
European Working Time Directive.1
Monthly returns from strategic health 
authorities seem to be at odds with the view from 
the medical frontline. The Department of Health 
is therefore working with the royal colleges to 
check the returns on an individual trust basis. 
The results should be available well before the 
deadline for derogation.
Although many trusts may have 48 hour 
compliant rotas on paper, the practicality of these 
rotas is worrying. UK medical registrars usually 
work 4 hours more than their contracted hours.2
Parliament has shown little sympathy for 
health professionals’ views on the working 
time directive because of lack of evidence of its 
negative effects beyond surveys of opinion. The 
profession needs to provide such evidence, and 
quickly, to get any MPs’ support. 
However, MPs support the opt-out for UK 
doctors from the directive. The opt-out gives 
additional flexibility for service provision and 
training opportunities, but it should not be seen 
as the only solution.
Doctors may not be aware of the large amount 
of recurrent money the Department of Health 
has given trusts to support the working time 
directive—for example, by employing additional 
acute physicians. This amounts to 0.2% of tariff 
income, or £300 000 a year for a typical acute 
trust. Some trusts may have kept this funding 
quiet to allow the money to be used elsewhere, 
but it is urgently needed if the directive is not to 
be the disaster we fear.
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“i Want to see tHe consultant”
Patients’ long and winding road
I have to ask whether Crampsey or any of his 
family or friends has experienced the long 
and frustrating road for patients referred to a 
“specialist,” particularly when the correct rapid 
diagnosis and management may mean the 
difference between life and death.1 The wait for 
the appointment, the sitting in a crowded waiting 
room for some hours, the eagerness to be put on 
the correct path immediately in order to survive. 
Who better to do that than the highly trained and 
experienced consultant, rather than the unknown 
quantity of a trainee with varying degrees of 
training, experience and ability, who may not 
necessarily defer to the consultant.
louise Spooner consultant anaesthetist, Boston, Lincolnshire 
lou.hr@tiscali.co.uk
Competing interests: None declared.
Crampsey DP. “I want to see the consultant”. 1 BMJ 
2009;338:b1399. (15 April.)
Cite this as: BMJ 2009;338:b1810
Continuity of care is important
 “I want to see the consultant” is often the most 
practical way for patients to state that they 
want continuity of care and a doctor-patient 
relationship based on trust.1 Our members most 
frequently complain that, on their outpatient 
check-ups every six months or annually, they 
have seen four different registrars or trainees 
on four consecutive visits, with the consultant’s 
experience or guidance an unspoken absence.
Several years ago we established an electronic 
discussion group (forum), and our members now 
explicitly discuss the variability in standards of 
treatment at UK hospitals.
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